Scientists re-engineer Patient's own cells to fight advanced lymphoma
NCT ID NCT03277729
First seen Jan 06, 2026 · Last updated Apr 13, 2026 · Updated 16 times
Summary
This study is testing a new cell therapy for adults with B-cell non-Hodgkin lymphomas or chronic lymphocytic leukemia that have come back or not responded to standard treatments. Doctors take a patient's own immune cells, genetically modify them to better target cancer, and infuse them back. The main goals are to find a safe dose and see if this approach can help control these difficult cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.